Squamous Cell Carcinoma News and Research RSS Feed - Squamous Cell Carcinoma News and Research

Squamous Cell Carcinoma is cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. Squamous cells are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts. Also called epidermoid carcinoma.
Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Clinicians and researchers from Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University will present new findings from eight abstracts at the International Federation of Head and Neck Oncologic Societies World Congress being held July 26 - July 30 in New York. [More]
Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School of Medicine at The University of Texas Health Science Center at San Antonio found. [More]
Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. [More]
TAZ represents a novel therapeutic target in NSCLC

TAZ represents a novel therapeutic target in NSCLC

Patients with non-small-cell lung cancer who express high levels of transcriptional coactivator with PDZ-binding motif may be a clinically distinct subgroup with an unfavourable prognosis, researchers report. [More]
New knowledge may expand treatments for patients with lung cancer

New knowledge may expand treatments for patients with lung cancer

Studying the most common type of lung cancer, researchers have uncovered mutations in a cell-signaling pathway that plays a role in forming tumors. [More]
TCGA finds novel mutations in key cancer-causing pathway in lung adenocarcinoma

TCGA finds novel mutations in key cancer-causing pathway in lung adenocarcinoma

Researchers from The Cancer Genome Atlas Research Network have identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, the most common subtype of lung cancer. [More]
FGFR1 amplification predicts poor outcome in early-stage NSCLC

FGFR1 amplification predicts poor outcome in early-stage NSCLC

Amplification of fibroblast growth factor receptor 1 is associated with poor clinical outcome in patients with early-stage non-small-cell lung cancer, Swiss researchers report. [More]
Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

Only 15% of patients with squamous cell lung cancer - the second most common lung cancer - survive five years past diagnosis. [More]
FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region. [More]
Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Advanced online publication in Nature: Researchers at the Université libre de Bruxelles, ULB uncover the molecular mechanisms regulating tumour initiation and cancer stem cells functions in skin squamous cell carcinoma. [More]
Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. [More]
Variations in BRCA2 and CHEK2 genes can increase lung cancer risk, study finds

Variations in BRCA2 and CHEK2 genes can increase lung cancer risk, study finds

New research confirms a vulnerability to lung cancer can be inherited and implicates the BRCA2 gene as harboring one of the involved genetic mutations. [More]
Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy. [More]

Study suggests proton therapy may be effective, less toxic treatment option for head and neck cancer

In a small study, researchers from The University of Texas MD Anderson Cancer Center found that 93 percent of head and neck cancer patients treated with multi-field optimization intensity modulated proton therapy (MFO-IMPT) were cancer-free 28 months after treatment. [More]
Vandetanib delays disease progression in elderly NSCLC patients

Vandetanib delays disease progression in elderly NSCLC patients

Vandetanib used in combination with gemcitabine significantly improves progression-free survival compared with gemcitabine alone when used as a first-line treatment for elderly patients with advanced non-small-cell lung cancer, Italian researchers report. [More]
Study to investigate use of OCT in collaboration with Melanoma Institute of Australia

Study to investigate use of OCT in collaboration with Melanoma Institute of Australia

Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, has commenced a clinical study to investigate the use of OCT to diagnose basal cell carcinoma in collaboration with the Melanoma Institute of Australia using Michelson's Diagnostics VivoSight system. [More]
Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

A study which will be published in the May 2014 issue of Experimental Biology and Medicine was aimed at determining whether an EGFR-targeted therapy combined with chemo-radiotherapy can improve local tumor control effectively, compared to cytotoxic agents or irradiation alone. [More]
New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1 [More]
RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). [More]
Researchers examine interaction between alcohol and tobacco in risk of ESCC

Researchers examine interaction between alcohol and tobacco in risk of ESCC

The rate of developing esophageal squamous cell carcinoma (ESCC) nearly doubles in those who both smoke and drink compared to those who only smoke or drink, according to new research published in The American Journal of Gastroenterology. [More]